
Sarb Shergill
Sarb Shergill has over 30 years of experience in drug development. Most recently Sarb was Corporate Vice President of Boston Global Development at Novo Nordisk leading programs in rare diseases and cardio-metabolic disorders.
Prior to Novo Nordisk, Sarb was SVP Clinical Operations and Data Management at ResTORbio Inc. a company focused on the development of drugs for the treatment of diseases related to aging.
Previously Sarb was VP Clinical Operations and Data Management at Akebia Therapeutics where she was responsible for leading the Phase 3 cardiac outcomes program in renal anemia. Sarb also worked at Sanofi following the acquisition of Genzyme Corporation. At Genzyme, she held positions of increasing responsibility and seniority, working in a number of therapeutic areas including rare diseases, CNS, oncology, cardiovascular and renal. Sarb has a PhD in Pharmacology from Liverpool John Moores University in the UK.